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Proton radiotherapy for treating the most common carcinomas
Beata Sas-Korczyńska1, Jerzy Jakubowicz1, Marian Reinfuss2 
A literature review is presented on proton radiotherapy when used for treating the most common carcinoma types 
such as cancer of the lung, breast and prostate. This is based on analytic parameters of dosimetry and clinical out-
comes (efficacy and toxicity), along with studies on cost-effectiveness as compared to those achieved by conventional 
photon radiotherapy. 
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Introduction
Technological advances made in radiotherapy have ena-
bled treatment outcomes to improve. After raising beam 
energy, (from kilo- to mega-volts), advanced technologies 
in radiation therapy have now become adapted in terms 
of equipment, methods of beam formation and advanced 
therapies such as Intensity-Modulated Radiation Therapy 
(IMRT), Stereotactic Body Radiation Therapy (SBRT), Dy-
namic Conformal Arc Therapy, Image-Guided Radiation 
Therapy (IGRT), Adaptive Radiation Therapy (ART) and the 
introduction of particle-based therapies (e.g. with protons, 
carbon ions) [1]. Although such progress has allowed a more 
precise dose to be delivered to the clinical target volume, 
the physical characteristics of the beam limit the sparing of 
healthy tissue in the instance of photon radiation therapy.
One solution is to use a proton beam whose physical 
properties, especially the manner in which energy is deposit-
ed (so-called Bragg curve), permit the proposed therapeutic 
dose to be precisely given to the clinical target volume whilst 
limiting the dose delivered to healthy tissue and/or critical 
organs that either surround the tumour or are in the path 
of the irradiating proton beam [2–4]. Proton radiotherapy 
thereby enables dose escalation without increasing any risk 
of developing side effects and complications (i.e. a so-called 
safe dose escalation).
The proton beam’s physical properties enable clinical 
indications to be determined, especially in defining low 
radiosensitive tumours localised within the vicinity of criti-
cal organs [3, 4].
Proton radiation therapy has been employed for the 
last 50 years of the twentieth century, where technology 
has steadily advanced from using a spread out Braag peak 
(SOBP) to an actively scanning beam (possible techniques 
of intensity-modulated proton therapy — IMPT) now used 
for improving dose distribution [1, 5–9]. As there are no 
randomised clinical trials for proton radiotherapy, it is only 
considered a standard procedure for intraocular choroidal 
melanoma (for preserving the eyeball and vision) as well as 
other rare tumours like those of the skull base and paediatric 
cancers, where the main priority is to limit the risk of devel-
oping complications. Within the last 90 years of the twen-
tieth century, the development of proton radiotherapy has 
occurred within clinical centres (previously this had been in 
centres for physics) for treating cancer, and not just for those 
aforementioned cancers at the so-called ”classical locations”.
In recent years, the number of cancer centres providing 
radiotherapy worldwide has been constantly increasing. Ac-
cording to the Particle Therapy Co-Operative Group (PTCOG), 
there were 63 such centres globally operating in the first 
quarter of 2016 with another 33 under construction; this 
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compares to just 28 operational centres from 2010. These 
increases, together with an increased use of proton radio-
therapy in not just for the non-classical clinical cases, have 
led to a steady increase in the number of treated patients, 
which in 2010 was 73,804 and rose to 118,195 in 2014 [10, 11].
The question now arises about using proton radiothera-
py for the most common cancers such as those of the lung, 
breast and prostate, which in 2012 were globally diagnosed 
as being respectively 1.8 million people (1.2 million males 
and 0.6 females), 1.7 million women and 1.1 million men [12]. 
In the same year in Poland, corresponding numbers for 
these cancers were respectively: 22 thousand (15 thousand 
males and 7 thousand females), 17 thousand and 11 thou-
sand [13, 14].
Non-small cell lung cancer (NSCLC)
Radiation therapy is a standard treatment procedure 
for cases of NSCLC that are either inoperable for medical 
reasons (I–II stage) or are at the advanced stage III [15]. 
However, this entails giving a sufficiently high radiation 
dose which has been confirmed by studies concerning the 
effects of escalating dose on local control (LC); for every 
1 Gy dose increment, the LC increases by 1% [16–19]. In cases 
of locally advanced stage III NSCLC, radiotherapy is used in 
combination with chemotherapy, usually as a concurrent 
therapy [15, 20–24].
A limiting factor in radiation therapy for NSCLC pa-
tients is that complications develop in the lungs and/or 
oesophagus which, for those at stage I–II, prevent the dose 
from being escalated whereas at stage III, this requires sub-
optimal combination treatment during simultaneous radio-
chemotherapy. The question thus arises whether proton 
radiotherapy can permit dose escalation because of the 
physical properties of the beam associated with the sparing 
of critical organs, when compared with photon radiation 
therapy and thereby improve treatment outcomes?
Studies that compare dosimetry (dose and tissue vol-
umes receiving defined dose levels) received by critical 
organs in NSCLC patients, both at first and third stage, show 
that using a proton beam significantly reduces the dose 
and volume of irradiated critical organs as well as the inte-
gral dose [23, 25–27]. This particularly applies to the tissue 
volume receiving low doses (e.g. a lung volume receiving 
a dose of 5 or 10 Gy i.e. the V5 or V10 value), as compared 
to photon radiation, where respectively a 2–3-fold and 
1.5–2-fold reduction of these values is observed for proton 
radiotherapy for stages I and III, even in cases of escalating 
the dose; 87.5 GyRBE vs 66 Gy [23]. Register et al. showed 
that compared to SBRT, proton radiotherapy when used 
on centrally located NSCLC I tumours significantly reduced 
the values: mean lung dose and lung volume receiving 5, 
10, and 20 Gy and the maximum doses to the aorta, heart, 
pulmonary vascular and spinal cord. The differences are 
particularly apparent for proton irradiation techniques used 
with intensity-modulated proton therapy (IMPT) employing 
the so-called pencil scanning beam [28]. The gains resulting 
from the ”sparing effect” of proton radiotherapy to critical 
organs is also observed in NSCLC III patients. A dosimetric 
study by Nichols et al. compared proton radiotherapy with 
3D CRT and IMRT, where the former showed a significant 
reduction in: lung volume receiving 20 Gy (V20), the mean 
lung dose (MLD), the bone marrow volume receiving 10 Gy 
(V10), the mean heart dose and the mean oesophageal dose. 
When compared to 3D CRT, the reductions were respectively 
29%, 33%, 30%, 66% and 22%, whilst compared to IMRT, the 
corresponding values were 26%, 31%, 27%, 42% and 12% [29].
Reducing the dose and the irradiated volume of critical 
organs results in the toxicity of radiation therapy being re-
duced. For proton radiotherapy, complications in the lungs 
or oesophagus at the G2 severity occur in several percent 
of patients, but G3 complications are rarely seen [30–44].
Such data indicate that thanks to the sparing of critical 
organs, proton radiotherapy reduces the rates and severi-
ties of complications, thereby it possesses the potential to 
improve the therapeutic index in patients with inoperable 
lung cancer and likewise for both I and III stages of NSCLC.
High efficacy and tolerance was found by applying hy-
pofractionation to proton radiotherapy when escalating 
the dose (50–70 GyRBE in 10 fractions or 15 fractions of 45– 
–60 GyRBE) in patients with early lung cancer [31, 33, 34, 36, 
38, 45]. Two-and 3-year overall survival (OS) rates ranged 
respectively 81–98% and 72–88% whilst for local control 
(LC) these were 80–97% and 74–96% respectively [33–36, 
38, 39, 46]. Failure rates ranged from 2–6% (loco-regional 
recurrence) to 17–22% (distant metastases) [34, 35, 38].
The possibility of safely escalating the doses in proton 
radiotherapy can also be used in NSCLC III, where LC can be 
improved, and hence the survival without increasing the risk 
of treatment-related mortality [23, 47]. Standard manage-
ment of NSCLC III patients consists of radio-chemotherapy, 
but is of limited efficacy since 50% of patients develop loco-
regional recurrence, which reduces overall survival [48–51]. 
Dose escalation in photon radiotherapy for treating NSCLC III 
patients is controversial, because the irradiated volume size 
is accompanied by severe complications and an increased 
risk mortality associated with this treatment.
Dosimetric parameters (e.g. V5, V30) regarding critical 
organs (e.g. lungs, oesophagus) are significant prognostic 
factors for overall survival rate [48, 52, 53]. Because proton 
beam enables possible ”sparing” of critical organs it can 
thereby potentially reduce complication rates, (e.g. radia-
tion pneumonitis observed in 8% versus 32% after photon 
radiation therapy) and thus promises improved treatment 
outcomes [47]. Studies from 2015 on NSCLC III patients, 
evaluating escalating dose tolerability of proton radiother-
apy when it was used concurrently with chemotherapy, 
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indicate that this procedure is well tolerated and that the 
2-year overall survival ranges 51–57% [43, 44].
A retrospective study by Sejpal et al., on the toxicity of 
various radiation therapy methods (proton beam vs 3D CRT 
vs IMRT) used in combination with chemotherapy, suggests 
that proton radiation therapy significantly reduces severe 
complication rates (G ≥ 3) in the lungs and oesophagus; rates 
being respectively 2%, 30%, 9% (complications in the lungs), 
and 5%, 18%, 44% (complications in the oesophagus). It 
should be noted that proton radiotherapy was administered 
at a higher dose to the tumour volume than for photon 
radiotherapy; 74 GyRBE vs 63 Gy [40]. Such study outcomes 
then became the basis for undertaking prospective studies. 
One such randomized trial study, compared toxicity and 
LC when using simultaneous chemotherapy with proton 
radiotherapy versus photon radiotherapy (used at doses 
of 66 and 74 GyRBE vs 74 Gy). Another was the RTOG phase 
III study, that assessed overall survival after radiotherapy at 
doses of 70 Gy (photon vs proton) when used concurrently 
with chemotherapy.
Breast cancer (BC)
Within the multidisciplinary treatment of breast cancer 
the role of radiotherapy is established post-mastectomy and 
breast-conserving therapy, of which it then forms an integral 
part. The advantages of postoperative radiotherapy is that it 
reduces rates of loco-regional failure and breast cancer mor-
tality, where such rates at 15-year follow-up are respectively 
19% and 5%. Unfortunately, such conferred benefits are 
handicapped by an increased risk of developing late cardiac 
complications. The mortality risk from cardiac complica-
tions increases with the time elapsing after treatment, and 
is found to be 1.27 at 15 years post-radiotherapy [54–57].
One of the clinical symptoms of cardiotoxicity related 
with radiotherapy is coronary heart disease, which is accom-
panied by the so-called major coronary events (MCE). The 
estimated MCE rates are 7.5% for every 1 Gy of mean heart 
dose [57]. Apart from dose, the risk of cardiac complications 
is significantly affected by the dose fractionation schedule 
adopted and the irradiated heart volume [58, 59]. In turn, 
the dose and the irradiated heart volume depends on the 
tumour location (in left vs in right breast), the size of the 
clinical target volume (irradiation with or without regional 
lymph nodes) and the radiotherapy technique used. In left-
-side cases, the risk of developing diseases of the coronary 
artery and mitral valve together with death from cardiac 
causes are respectively 1.25, 1.54 and 1.58 when compared 
to the right-side of breast cancer [60, 61].
Studies that compare dosimetry parameters for radiother-
apy in BC patients, indicate that the irradiated heart volume, 
which receive high or low dose (V20, V5), is reduced when 
using a proton beam compared with photon beams; where 
mean heart doses are respectively 19 Gy vs 23–25 Gy [62–68]. 
The probability of cardiac complications was estimated at 
0.5% for the proton beam and 2.1% for the photon beam 
radiotherapy [69].
Proton radiotherapy, as compared with the photon 
counterpart, allows a more homogeneous irradiation with 
a high dose target volume with limited doses delivered to 
the heart, lung and the opposite breast which is a particular 
advantage of IMPT [70–73]. This is particularly relevant for 
clinical situations where irradiation of regional lymph nodes 
is required. When compared to photon radiotherapy, a study 
by Bradley et al. indicated that proton radiotherapy, either at 
post-mastectomy or breast-conserving treatment, not only 
provides a substantially superior irradiation coverage at 
a high dose (D95) of the nodal target volume but also reduces 
average dose values: V5 in the heart (0.6% vs 16.3%), V5 and 
V20 in the lung (respectively 35.3% and 21.6% vs 60.5% and 
35.5%) [81]. A study by McDonald et al. compared V5 value in 
the heart using different radiation therapy techniques post-
mastectomy, which found 36% for the photon-electron, 21% 
for photon and 4% for proton beam used in radiotherapy [74].
The sparing effects of proton radiotherapy on critical or-
gans is particularly apparent in cases of left-sided BC where 
using IMPT, as compared with IMRT, allowed a 20-fold reduc-
tion of heart dose and for the left anterior descendens (LAD) 
artery region (a lower arm of the left coronary artery), which 
is a critical structure in the development of late cardiac 
complications [67, 75–80]. Such findings are indicative of 
a potential benefit in using proton radiotherapy for adjuvant 
radiotherapy of BC patients, especially when risk factors for 
cardiac complications are present [80].
Some clinical studies have evaluated cosmetic effects 
and skin tolerance in BC patients treated by proton radio-
therapy. Doses ranging at 30–50 GyRBE in 10–24 fractions are 
well tolerated; skin reactions of G1–2 severity are observed 
in 60–79% cases, telangiectasia at G1 grade in 15–26% and 
a cosmetic effect, self-assessed by the patients, as being 
good or satisfactory in 80–90% [65, 81–84].
Studies have also taken advantage of accelerated par-
tial breast irradiation (APBI) [85, 86]. The efficacy of proton 
radiotherapy is similar to other radiotherapy techniques 
used in such cases, with 5-year disease-free survival and 
overall survival rates being respectively 94% and 95% [81]. 
Dosimetric comparisons of various APBI techniques demon-
strate that proton radiotherapy, when compared with IMRT 
and brachytherapy, significantly reduces the maximum dose 
delivered to health breast tissue, the mean heart dose, the 
mean chest wall dose and the mean lung dose [87]. Findings 
by Girodet-Galland et al. show that symptoms of skin reac-
tions are more common in proton radiotherapy compared to 
photon radiotherapy [82]. Recommendations for BC patients 
undergoing proton radiotherapy is to use multiple beams 
at each fraction of radiotherapy, or using scanning beams 
which improves tolerance and cosmetic outcomes [82, 83].
399
Prostate cancer (PC)
The efficacy of radiotherapy for treating PC patients 
depends on the dose delivered to the target volume as 
confirmed by randomised studies which escalate the dose 
up to the 76–79 Gy level as used in external beam radio-
therapy [88–91]. Development of complications cannot be 
completely ruled out when doses are deposited to critical 
organs by advanced techniques (e.g. IMRT, arc and helical 
radiotherapy techniques) that employ modern technolo-
gies (e.g. image guided radiation therapy or adaptive ra-
diotherapy); this also applying to the risk of developing 
complications to the gastrointestinal tract and urogenital 
system along with the risk of secondary tumours [92, 93].
Due to its physical properties, proton radiotherapy of-
fers the potential for further reducing the risk of developing 
complications. Dosimetry studies have shown a 30–50% 
dose reduction to critical organs when using proton beam 
compared with the photon beam, even when advanced 
radiotherapy techniques are applied [94–100]. Reducing the 
mean dose of the rectum or its wall, the bladder and small 
intestine, (and regrettably increasing the dose to femoral 
bone heads) is observed in cases where the proton beam 
is used as booster in IMRT [101].
Clinical findings indicate that in cases of early tolerance, 
developing complications at G2 and G3 grades is respec-
tively 5–12% and 1–2% likely for the urinary tract but is re-
spectively less than 3.5% and 0.5% for the rectum [95, 96, 99]. 
With the passing of time after treatment, complication rates 
rise after 5 years at the G2 level; 21–31% in the urinary tract 
and 10–18% in the rectum [88, 95, 96, 102–107]. It should be 
emphasised that late complications are more common for 
those patients where attempts at dose escalation were made 
using proton radiotherapy alone or in the booster form 
after conventional radiation therapy [103, 107, 109]. A ran-
domised phase III study by Shipley et al. indeed confirmed 
this, where the efficacy of 75.6 Gy (photon radiotherapy 
with proton “boost”) vs 67.2 Gy (photon radiotherapy) was 
compared. Within 8-year post-treatment, complication rates 
for the rectum and the urinary tract were 32% and 19% re-
spectively when proton radiotherapy was administered as 
a “boost” to photon radiotherapy as respectively compared 
to 12% and 8% rates when proton radiotherapy was used 
alone [109]. Retrospective studies on early toxicity showed 
that the complication rates were statistically significantly 
reduced in the urinary tract during 6 months after proton 
radiotherapy compared to IMRT, but such differences gradu-
ally diminished with time of observation [102].
Other clinical data has demonstrated clear differences in 
complication rates for the gastrointestinal tract, where the 
less toxic method proved to be photon radiotherapy using 
the IMRT technique [110]. An assessment of the quality of 
life (QOL), through comparing proton radiotherapy with 
IMRT, Hoppe et al. showed no differences in summation 
scales for the intestine, urinary incontinence, urinary tract 
obstruction and libido. Rectal symptoms were the only ones 
different, which occurred more frequently after IMRT [111].
A randomized study by Zietman et al. which compared 
proton “boost” doses of 19.8 GyRBE vs 28.8 GyRBE given after 
photon beam dose of 50.4 Gy, showed that after administer-
ing the total doses of respectively 70.2 Gy vs 79.2 Gy, the 
former had significantly lower rates of biochemical failure 
than the latter; 32.4% vs 16.6% (p < 0.0001). No significant 
differences in the rates and severity of side effects were 
however found, nor in overall survival rates [88, 103].
Proton radiotherapy is also used as a stand-alone ra-
diotherapy so that doses can be increased to 74–78 GyRBE 
by conventional fractionation or in hypofractionation dose 
regimens of 35–60 GyRBE in 5–20 fractions [99, 104, 106, 107]. 
Outcomes from these procedures demonstrate high efficacy 
but low toxicity. After five years, biochemically recurrence-
-free survival was 93–100% (low risk PC), 85–99% (inter-
mediate risk PC) and 74–76% (high risk PC). A prospective 
randomised study by Vargas et al. compared two doses of 
proton radiotherapy (i.e. 38 GyRBE in 5 fractions vs 79.2 GyRBE 
in 44 fractions) and found similar efficacy and tolerability for 
both. Nor were any differences seen between these groups 
in their quality of life using the EPIC scale (Expanded Prostate 
Index Composite) [112].
Although proton radiotherapy enables dose escalation 
without increased early toxicity (both in “boost” and stand-
alone modes), this effect is nevertheless lost over time after 
treatment in cases of symptoms found in the gastrointestinal 
and urinary tracts.
Conclusions
Despite the undoubted advantages of proton radio-
therapy, it is still considered a study method. Reasons for 
this are the lack of modern and controlled clinical trials that 
compare this method with current photon radiotherapy 
techniques, as well as its high operating costs. Even though 
there have been clinical studies for the last 60 years on 
proton radiotherapy, these have been on relatively small 
numbers of patients which, particularly in the case of com-
mon cancers, not only precludes formulating definitive rec-
ommendations but makes it even difficult to come to any 
preliminary conclusions. A classic example is the problem of 
comparing toxicity and efficacy of proton radiotherapy with 
brachytherapy in patients suffering early prostate cancer.
A cost-effectiveness analysis by Verma et al. [113] showed 
that proton radiotherapy is cost-effectiveness (based on 
QALY which is quality-adjusted life-years) for paediatric 
brain tumours, well-selected breast cancer, locoregionally 
advanced lung cancer and in head & neck cancers with 
a high risk of toxicity to the mucous membrane. In cases of 
prostate and early lung cancers, this technique has however 
not shown to be cost-effective as a medical procedure.
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Thus for most common cancers, the “entrance door” 
to the widespread use of proton radiotherapy may only 
be opened through modern and controlled clinical trials. 
This assumes that its superiority over photon radiotherapy 
can be demonstrated in terms of toxicity, local control and 
overall survival, together with lowered operating costs.
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